triamcinolone and bevacizumab

Phase 3Monoclonal antibody

JJohann Wolfgang Goethe University Hospital

triamcinolone and bevacizumab is one of 65 small molecule programs targeting Retinal Vein Occlusion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal Vein OcclusionActive, not recruiting

Diabetic RetinopathyActive, not recruiting

Retinal Vein OcclusionPhase 3

Active, not recruiting

Diabetic RetinopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

99 competitors in Diabetic Retinopathy

#DrugCompanyPhaseTrials

Atacand

AstraZeneca

Phase 3

2 2

Bayer Aspirin

Bayer

Phase 3

1 3

Sandostatin

Novartis

Phase 3

—4

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

2 5

Zocor

OOrganon and Co

Phase 3

2 6

Avastin

BBio-Thera Solutions

Phase 3

1 7

Atacand

IIstituto Clinico Humanitas

Phase 3

1 8

Octreotide Depot

Novartis

Phase 3

2 9

Pred Forte

Novartis

Phase 2

1 10

Alphagan

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinal Vein Occlusion1 trial

Combined Triple Procedure in Retinal Vein Occlusion (RVO)

Completed·JJohann Wolfgang Goethe University Hospital·Phase 3·NCT00805064·40 enrolled

Diabetic Retinopathy1 trial

Combined Triple Therapy in Diabetic Retinopathy (DRP)

Completed·JJohann Wolfgang Goethe University Hospital·Phase 3·NCT00806169·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for triamcinolone and bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — triamcinolone and bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for triamcinolone and bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johann Wolfgang Goethe University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: JJohann Wolfgang Goethe University Hospital

triamcinolone and bevacizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Retinal Vein Occlusion1 trial

Diabetic Retinopathy1 trial

References

Drug Info

Quick Facts

Related News